Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.46 |
| ▸ | MEN1 | O00255 | 5/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.46 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4033384 | 0.84 | SLC40A1 (0.45) | SLC40A1KMT2AMEN1NPC1HTT | |
| SCHEMBL4029308 | 0.82 | MEN1 (0.47) | SLC40A1KMT2AMEN1NPC1HSP90AA1 | |
| SCHEMBL4027701 | 0.81 | ALDH1A1 (0.55) | SLC40A1KMT2AMEN1NPC1HSP90AA1 | |
| SCHEMBL21490844 | 0.74 | PTGDR2 (0.46) | SLC40A1KMT2AMEN1NPC1HSP90AA1 | |
| SCHEMBL4029234 | 0.71 | KMT2A (0.49) | SLC40A1KMT2AMEN1NPC1HSP90AA1 | |
| SCHEMBL13812016 | 0.70 | SLC40A1 (0.42) | SLC40A1KMT2AMEN1NPC1HSP90AA1 | |
| SCHEMBL1749021 | 0.68 | PTGDR2 (0.44) | SLC40A1KMT2AMEN1NPC1HSP90AA1 | |
| SCHEMBL4031312 | 0.68 | SLC40A1 (0.42) | SLC40A1KMT2AMEN1NPC1HSP90AA1 | |
| SCHEMBL19643722 | 0.67 | PTGDR2 (0.45) | HTTALDH1A1KDM4ELMNAL3MBTL1 | |
| SCHEMBL1749228 | 0.66 | L3MBTL1 (0.59) | HTTALDH1A1KDM4EPOLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1307454-B1 | DERIVATIVES OF VARIOLIN B | PHARMA MAR SA (ES) | 2009-06-03 | — | — | EP | disclosed |
| US-7329666-B2 | Derivatives of variolin B | PHARMA MAR, S.A. (ES) | 2008-02-12 | — | — | US | disclosed |
| US-20080033001-A1 | Derivatives of Variolin B | UNIVERSIDAD DE BARCELONA (ES) | 2008-02-07 | — | — | US | disclosed |
| US-20040058939-A1 | Derivatives of variolin b | PHARMA MAR, S.A. (ES) | 2004-03-25 | — | — | US | disclosed |
| EP-1307454-A1 | DERIVATIVES OF VARIOLIN B | Universidad de Barcelona (ES) | 2003-05-07 | — | — | EP | disclosed |
| WO-2002012240-A1 | DERIVATIVES OF VARIOLIN B | UNIVERSIDAD DE BARCELONA (ES) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033001-A1 | Derivatives of Variolin B | ARG2, SDHB, OAT | SLC40A1 535/4885KMT2A 1287/4885MEN1 2136/4885 |
| US-20040058939-A1 | Derivatives of variolin b | HNRNPA2B1, HNRNPAB, SYNCRIP | SLC40A1 793/4885KMT2A 1337/4885MEN1 2386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.